ImmunityBio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IBRX Nasdaq 2836 immunitybio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ImmunityBio, Inc.

SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot - Oct 2nd, 2026 1:02 am
IBRX Stock Racks Up 3 Straight Quarterly Wins: Q3 Filings Reveal BlackRock Closing In On Vanguard With A Bigger Bet - Sep 30th, 2026 9:18 pm
IBRX Breaks Above This Key Resistance — Stock On Track To Record Best Single-Day Gains In 6 Months - Sep 30th, 2026 10:37 am
A $5.8B Cancer Market Opportunity Is Emerging — Why GA-Courtenay Favors ImmunityBio (IBRX) - Sep 30th, 2026 6:28 am
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump? - Sep 29th, 2026 9:47 pm
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10% - Sep 22nd, 2026 6:26 pm
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode - Sep 21st, 2026 12:49 am
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last? - Sep 18th, 2026 1:41 am
ImmunityBio (IBRX) Moved, So What Is Drawing Fresh Attention? - Sep 15th, 2026 8:12 pm
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals - Sep 14th, 2026 10:00 pm
IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet - Sep 14th, 2026 5:29 pm
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors - Sep 14th, 2026 8:30 am
SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck - Sep 14th, 2026 2:47 am
IBRX Stock Eyes Worst Week Since July: New Patent Eyes Broader Anktiva Use Ahead Of Lung Cancer Conference - Sep 11th, 2026 2:04 am
SLS, IBRX In Focus: Canadian Insurance Giant Manulife’s Unit Raises Stakes Ahead Of Key Cancer Catalysts - Sep 9th, 2026 9:03 pm
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue? - Sep 4th, 2026 9:30 am
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’ - Sep 1st, 2026 12:09 am
IBRX Stock Heads For Best Week In Over 2 Months After Chairman Soon Shiong’s Cancer Vaccine Trial Milestone Update - Aug 27th, 2026 11:57 am
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future - Aug 27th, 2026 1:09 am